Capricor Therapeutics
Overview
Capricor Therapeutics is a clinical-stage biopharmaceutical company focused on developing regenerative medicine and exosome-based therapies for neurodegenerative diseases and cardiovascular conditions. Founded in 2005, the company has established itself as a leader in therapeutic exosome technology, particularly in leveraging cardiosphere-derived cell (CDC) exosomes for treating age-related neurological decline and neuroinflammatory conditions. Capricor's research platform centers on understanding how exosomal particles can modulate disease pathways implicated in multiple neurodegenerative conditions, including cognitive decline associated with aging and neuroinflammation-driven neuronal loss.
Function/Biology
Capricor's lead therapeutic approach involves the isolation and characterization of exosomes derived from cardiosphere-derived cells—a population of cardiac progenitor cells with potent regenerative properties. Exosomes are extracellular vesicles approximately 30-150 nanometers in diameter that function as intercellular communication vehicles, transporting proteins, lipids, and nucleic acids between cells. CDC-derived exosomes contain a rich cargo of bioactive molecules, including growth factors, microRNAs, and signaling proteins that can cross biological barriers, including the blood-brain barrier, enabling delivery to the central nervous system.
...Capricor Therapeutics
Overview
Capricor Therapeutics is a clinical-stage biopharmaceutical company focused on developing regenerative medicine and exosome-based therapies for neurodegenerative diseases and cardiovascular conditions. Founded in 2005, the company has established itself as a leader in therapeutic exosome technology, particularly in leveraging cardiosphere-derived cell (CDC) exosomes for treating age-related neurological decline and neuroinflammatory conditions. Capricor's research platform centers on understanding how exosomal particles can modulate disease pathways implicated in multiple neurodegenerative conditions, including cognitive decline associated with aging and neuroinflammation-driven neuronal loss.
Function/Biology
Capricor's lead therapeutic approach involves the isolation and characterization of exosomes derived from cardiosphere-derived cells—a population of cardiac progenitor cells with potent regenerative properties. Exosomes are extracellular vesicles approximately 30-150 nanometers in diameter that function as intercellular communication vehicles, transporting proteins, lipids, and nucleic acids between cells. CDC-derived exosomes contain a rich cargo of bioactive molecules, including growth factors, microRNAs, and signaling proteins that can cross biological barriers, including the blood-brain barrier, enabling delivery to the central nervous system.
These exosomes are thought to work through multiple biological mechanisms: they suppress excessive microglial activation, reduce production of pro-inflammatory cytokines, promote neuronal survival and plasticity, and enhance mitochondrial function in affected neurons. The cargo within CDC exosomes includes miR-181b, which has been identified as a key regulator of neuroinflammatory responses. Additionally, these exosomes interact with cell surface receptors and can modulate key signaling pathways relevant to neurodegeneration, including pathways regulated by SIRT6 (sirtuin 6), a NAD-dependent deacetylase implicated in longevity and stress resistance.
Role in Neurodegeneration
Capricor Therapeutics targets age-related cognitive decline and associated neuroinflammatory pathways that contribute to neurodegenerative disease progression. Neuroinflammation, characterized by sustained activation of microglia and astrocytes, represents a major contributor to neuronal death in Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions. The company's therapeutic approach addresses this problem by delivering exosomes that actively inhibit neuroinflammatory cascades while simultaneously promoting neuroprotection.
The exosomal therapy framework is particularly relevant to understanding age-related cognitive decline, where accumulated cellular stress, mitochondrial dysfunction, and chronic immune activation drive neuronal loss. By modulating these pathways, Capricor's candidates may slow or potentially reverse cognitive decline in aging populations. The company's research has also explored connections between their therapeutic approach and the regulation of chemokine signaling, particularly through the CX3CR1 (CX3C chemokine receptor 1) pathway, which plays critical roles in microglial recruitment and neuroinflammatory responses.
Molecular Mechanisms
Capricor's exosome-based therapeutics operate through several integrated molecular mechanisms. The exosomes suppress microglial activation through toll-like receptor modulation and NLRP3 inflammasome inhibition, thereby reducing production of IL-1β, TNF-α, and IL-6. This anti-inflammatory activity protects neurons from cytokine-mediated death signals. Simultaneously, exosomal cargo promotes neurotrophic signaling through interaction with receptors including TrkB (tropomyosin receptor kinase B), enhancing neuronal survival and synaptic plasticity.
The company has investigated connections to AADC (aromatic L-amino acid decarboxylase), an enzyme critical for neurotransmitter synthesis, suggesting potential applications in conditions involving dopaminergic dysfunction. Furthermore, the exosomes' bioactive components interact with stress-response pathways regulated by SIRT6, activating cellular defense mechanisms against oxidative stress and proteotoxic accumulation—hallmarks of neurodegeneration.
Clinical/Research Significance
Capricor's exosome platform represents a novel approach to addressing fundamental pathological processes in neurodegeneration rather than targeting single disease-specific proteins. This broad-spectrum mechanism may provide therapeutic benefits across multiple neurodegenerative indications. The company's development of scalable exosome manufacturing processes has implications for accessibility and clinical translation. Preclinical studies have demonstrated efficacy in models of cognitive decline and neuroinflammation, supporting progression toward human clinical trials.
Capricor Therapeutics collaborates with academic institutions and research centers studying neuroinflammation, exosomal biology, and regenerative medicine. The company's work intersects with broader research on microglial biology, sirtuin signaling, and chemokine-mediated immune responses in the central nervous system, positioning it within a network of regenerative medicine and neuroimmunology research organizations.